0.23
price down icon6.20%   -0.0152
after-market Handel nachbörslich: .24 0.010 +4.35%
loading
Schlusskurs vom Vortag:
$0.2452
Offen:
$0.24
24-Stunden-Volumen:
139.37K
Relative Volume:
0.07
Marktkapitalisierung:
$47.35M
Einnahmen:
$74,000
Nettoeinkommen (Verlust:
$-13.43M
KGV:
-0.0245
EPS:
-9.4
Netto-Cashflow:
$-10.54M
1W Leistung:
-24.79%
1M Leistung:
-28.66%
6M Leistung:
-75.00%
1J Leistung:
-89.50%
1-Tages-Spanne:
Value
$0.23
$0.25
1-Wochen-Bereich:
Value
$0.2215
$0.307
52-Wochen-Spanne:
Value
$0.2215
$4.00

Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile

Name
Firmenname
Cyclacel Pharmaceuticals Inc
Name
Telefon
908-517-7330
Name
Adresse
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
CYCC's Discussions on Twitter

Vergleichen Sie CYCC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CYCC
Cyclacel Pharmaceuticals Inc
0.23 47.35M 74,000 -13.43M -10.54M -9.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-07-18 Fortgesetzt Oppenheimer Outperform
2020-04-27 Fortgesetzt ROTH Capital Buy
2018-09-07 Eingeleitet Ladenburg Thalmann Buy
2015-10-16 Eingeleitet H.C. Wainwright Buy
2010-02-04 Eingeleitet Roth Capital Buy
2009-10-28 Eingeleitet Merriman Buy
2008-08-12 Eingeleitet Piper Jaffray Buy
2008-03-12 Bestätigt Cantor Fitzgerald Buy
2008-03-12 Bestätigt Collins Stewart Buy
2008-03-12 Bestätigt Needham & Co Buy
2007-11-27 Bestätigt Cantor Fitzgerald Buy
2007-08-10 Bestätigt Cantor Fitzgerald Buy
2007-06-04 Bestätigt Needham & Co Buy
2007-04-23 Eingeleitet Lazard Capital Buy
2007-04-10 Eingeleitet Cantor Fitzgerald Buy
Alle ansehen

Cyclacel Pharmaceuticals Inc Aktie (CYCC) Neueste Nachrichten

pulisher
12:41 PM

Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development - TipRanks

12:41 PM
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Slashes Net Loss in Half, Streamlines to Focus on Promising Cancer Drug - Stock Titan

Apr 02, 2025
pulisher
Mar 31, 2025

Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 31, 2025
pulisher
Mar 26, 2025

Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN

Mar 26, 2025
pulisher
Mar 24, 2025

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 - Stock Titan

Mar 24, 2025
pulisher
Mar 23, 2025

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World

Mar 23, 2025
pulisher
Mar 17, 2025

Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle

Mar 17, 2025
pulisher
Mar 17, 2025

(CYCCP) Trading Advice - news.stocktradersdaily.com

Mar 17, 2025
pulisher
Mar 16, 2025

Cyclacel Pharmaceuticals (CYCC) Projected to Post Earnings on Tuesday - The AM Reporter

Mar 16, 2025
pulisher
Mar 15, 2025

CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025
pulisher
Mar 15, 2025

StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com

Mar 14, 2025
pulisher
Mar 12, 2025

Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN

Mar 09, 2025
pulisher
Mar 07, 2025

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 28, 2025

Cyclacel Pharmaceuticals interim CEO David Lazar sells $5.5 million in stock - Investing.com India

Feb 28, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Announces New Leadership and Restructuring - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Says Datuk Dr.Doris Wong Sing Ee Elected As CEO & Executive Director - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Expands Executive Leadership Team - citybiz

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Who Now Controls Cyclacel? New Investor Takes 70% Ownership in $6.3M Leadership Overhaul - StockTitan

Feb 27, 2025
pulisher
Feb 26, 2025

Buffett’s on the Sidelines – Should You Follow? - The Globe and Mail

Feb 26, 2025
pulisher
Feb 24, 2025

Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News

Feb 24, 2025
pulisher
Feb 24, 2025

Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

(CYCCP) Trading Report - news.stocktradersdaily.com

Feb 24, 2025
pulisher
Feb 23, 2025

Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World

Feb 23, 2025
pulisher
Feb 17, 2025

Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com

Feb 17, 2025
pulisher
Feb 16, 2025

Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN

Feb 16, 2025

Finanzdaten der Cyclacel Pharmaceuticals Inc-Aktie (CYCC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):